Characteristics of tumor patients with anti-P1 antibody: a retrospective study
Journal Title: Chinese Journal of Blood Transfusion - Year 2023, Vol 36, Issue 3
Abstract
Objective To evaluate the detection and distribution characteristics of anti-P1 in tumor patients, so as to aid in blood screening and transfusion safety. Methods The clinical data of 112 658 tumor patients who underwent blood preparation and transfusion in our hospital from January 2014 to December 2021 were retrospectively analyzed, and column agglutination technique was used to perform transfusion compatibility test. Results A total of 1 079 (0.96%, 1 079/112 658) cases were detected with unexpected antibodies, of which 71 (6.58%, 71/1 079) were identified as anti-P1. In anti-P1 cases, 59.15% (42/71) were males; 60.56% had no pregnancy history (P<0.01); 29.58% (21/71), 52.11%(37/71), 12.68%(9/71) and 5.63%(4/71) of anti-P1 patients were with type A, B, O and AB, respectively. 57 cases of anti-P1 patients (80.28%) had difficulty in ABO blood group identification. The incidence of interfering in patients with type B was higher than that of other blood types (P<0.05), as the frequency of w+ in reverse blood typing was higher than other reactive patterns (P<0.05). The incidence of gastric tumor and brain space-occupying lesion in patients with anti-P1 was higher than that in patients with other alloantibodies, while the incidence of gynecological tumors was lower (P<0.05). Conclusion Anti-P1 affects the ABO blood group identification of tumor patients, and most of them had difficulty in ABO blood group identification. Compared with patients with other alloantibodies, patients with anti-P1 are more likely to be male and suffer from gastric and brain tumors, but less likely from gynecological tumors.
Authors and Affiliations
Simeng CHEN, Jingjing YU, Juan CAI, Min LIU, Tao PENG, Weiwei FANG, Ruijuan ZHAO, Xiying LI
Keywords
Related Articles
- EP ID EP738509
- DOI 10.13303/j.cjbt.issn.1004-549x.2023.03.010
- Views 66
- Downloads 0
Matching strategy for patients with platelet transfusion refractoriness caused by compound antibodies against HLA and CD36
Objective To search compatible and suitable platelets for platelet transfusion refractoriness (PTR) patient caused by compound antibodies against HLA and CD36. Methods ELISA method was used to detect the antibody against...
Changes of blood indicators in blood donors after COVID-19 vaccination
Objective To explore the changes of blood routine, biochemical indexes and coagulation indexes of voluntary blood donors after COVID-19 vaccination, so as to provide a scientific basis for blood donation strategy and to...
Blood immunological analysis of hemolytic disease of the fetus and newborn caused by Rh deletion type D--
Objective To analyze the causes of a case of hemolytic disease of the fetus and newborn (HDFN),and investigate the genetic background of maternal Rh deletion D--formation. Methods Blood samples of maternal and fetus were...
Development of a national health standard: Guideline for pediatric transfusion
Children and adults differ significantly in physiology, biochemistry and immune function, which leads to significant differences in blood transfusion strategies between children and adults. To guide the clinical transfus...
Expert consensus on RhD blood group testing strategies in blood transfusion compatibility testing laboratories
RhD antigen is the most immunogenic antigens in the Rh blood group system and can cause hemolytic transfusion reactions (HTRs) and severe hemolytic disease of the fetus and newborn (HDFN). RhD-negative red blood cell (RB...